The FDA and the "Cuffless" Challenge
A major regulatory milestone occurred on January 23, 2026, when the FDA released the draft guidance "Cuffless Non-Invasive Blood Pressure Measuring Devices."
The Validity Gap: While smart rings (Oura Ring 4, Samsung Galaxy Ring) and watches are popular in 2026, the FDA has clarified that they are currently "Wellness" devices rather than "Medical" diagnostics.
Calibration Requirements: Most 2026 cuffless devices still require a traditional inflatable cuff for "initialization" every 28 days to ensure the AI algorithms remain calibrated to the patient's unique vascular tone.
Standardized Benchmarks: The FDA now recommends that all BP sensors demonstrate a mean error of ≤ ±5.0 mmHg to be considered for clinical use, a hurdle that has kept the inflatable cuff as the "anchor" of hypertension management.